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Summary. The role of platelets in hemostasis and throm-
bosis is dependent on a complex balance of activatory and
inhibitory signaling pathways. Inhibitory signals released
from the healthy vasculature suppress platelet activation in
the absence of platelet receptor agonists. Activatory signals
present at a site of injury initiate platelet activation and
thrombus formation; subsequently, endogenous negative
signaling regulators dampen activatory signals to control
thrombus growth. Understanding the complex interplay
between activatory and inhibitory signaling networks is an
emerging challenge in the study of platelet biology, and
necessitates a systematic approach to utilize experimental
data effectively. In this review, we will explore the key
points of platelet regulation and signaling that maintain
platelets in a resting state, mediate activation to elicit
thrombus formation, or provide negative feedback. Platelet
signaling will be described in terms of key signaling mole-
cules that are common to the pathways activated by plate-
let agonists and can be described as regulatory nodes for
both positive and negative regulators.
Keywords: blood platelets; hemostasis; platelet activation;
review; thrombosis.
Introduction
The primary role of platelets lies in their ability to form
aggregates when they encounter areas of blood vessel
damage, allowing them to limit blood loss by forming a
hemostatic clot. The capacity of platelets to aggregate
also forms the basis of their role in disease, whereby pla-
telet thrombus formation is triggered by an inappropriate
stimulus such as the rupture of an atherosclerotic plaque.
If the thrombus causes vessel occlusion in the heart or
brain, this can result in a heart attack or stroke. The way
in which platelets respond to their environment, often
referred to as ‘platelet function’, defines their ability to
fulfill their role in hemostasis and also their propensity to
contribute towards disease. The environmental stimuli
encountered by platelets are complex, as are the intracel-
lular signaling pathways that regulate their responses to
these stimuli.
To understand how platelets function within the vascu-
lature, the three types of signals encountered by platelets
and the signaling responses that they trigger must be con-
sidered simultaneously. Platelets encounter inhibitory sig-
nals that keep them in a quiescent state in the healthy
vasculature, activatory signals at sites of vascular damage
that rapidly trigger adhesion and aggregation, and nega-
tive regulatory signals that provide negative feedback
once platelet activation is initiated and serve to limit
thrombus formation (Fig. 1). There is a problem, how-
ever, with the conventional models used to understand
platelet signaling. Platelets experience numerous extracel-
lular signals at the same time and respond to complex
combinations of primary and secondary activatory signals
in addition to opposing inhibitory signals, yet we concep-
tualize such regulation as distinct linear pathways, each
of which is triggered in response to a single agonist. This
simplified approach is useful for designing experiments to
delineate the order of events, but a more sophisticated
approach is needed to incorporate multiple agonists and
pathways, which themselves crosstalk, into a signaling
network. Understanding these complex interacting signal-
ing pathways as networks is a challenge that can only
ultimately be met by systematic approaches that seek to
model complex systems with many interacting parts. Sys-
tematic strategies that enable a holistic view of platelet
function will be important to support the development of
new antiplatelet therapies and new diagnostic methods,
and successful prediction of hemostatic side effects for
non-platelet-targeting drugs.
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Many of the complex positive and negative platelet sig-
naling pathways converge on key regulators of platelet
signaling. By understanding how platelets regulate impor-
tant signaling molecules such as phospholipase C (PLC),
protein kinase C (PKC), and phosphatidylinositide-3-
kinase (PI3K), which underpin critical events in platelet
activation such as granule secretion and integrin aIIbb3
activation, we can understand the factors that define pla-
telet function. In this review of platelet signaling path-
ways, we will refrain from describing signaling pathways
as such, and instead focus on the impact of molecules
that activate or inhibit platelet function on the core sig-
naling processes that control platelet function, to begin to
appreciate the interconnectedness of these systems.
Regulators of platelet inhibition
Within the vasculature, platelets exist in a complex, flow-
ing environment where both rheologic and hemodynamic
factors force platelets into close proximity to the vessel
wall. The signals generated by healthy, undamaged blood
vessels promote quiescence, and allow platelets to circu-
late in a resting state [1]. Without inhibitory signaling
mechanisms, platelets would become activated even in the
absence of activating signals. Circumstances in which
these inhibitory signals are defective or activatory factors
are exposed can lead to inappropriate platelet activation
and cause ischemic heart disease or stroke [2].
The inhibitory signaling pathways are relatively few in
number, but suppress several key nodes in the platelet sig-
naling network that support activation. The primary pla-
telet-inhibiting signals generated by healthy, intact
vascular endothelial cells are nitric oxide (NO) and
prostacyclin (prostaglandin I2 [PGI2]), which regulate
levels of intracellular cyclic nucleotides that suppress pla-
telet activity by activating protein kinase G (PKG) and
protein kinase A (PKA). [2].
NO and PGI2
NO suppresses platelet activation by regulating intracellu-
lar levels of cGMP [3] via the activation of soluble guanyl
cyclase, which regulates PKG activity. PGI2 binds to the
prostaglandin receptor (IP receptor) on the platelet sur-
face [4], and activates G-protein a-s-coupled G-protein-
coupled receptors (GPCRs). The active GTP-bound form
of Gs then binds to and activates adenylyl cyclase, and
stimulates the production of cAMP from AMP [5], which
in turn causes the activation of cAMP-dependent PKA.
Many substrates of PKA and PKG are yet to be thor-
oughly characterized, but there is significant overlap in
the well-established targets. These targets include regula-
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Fig. 1. Stages of platelet activation and thrombus formation. Platelets in the circulation are kept in a quiescent state by nitric oxide (NO) and
prostacyclin (prostaglandin I2; PGI2), which are released by the vascular endothelium. In platelets, NO and PGI2 increase the levels of cGMP
and cAMP, and suppress platelet activity by the activation of protein kinase A (PKA) and protein kinase G (PKG). Following vessel injury,
components of the subendothelial matrix are exposed, including collagen, which provides an adhesive surface for platelets to attach to and initi-
ate signaling events and platelet activation. Local production of thrombin and secretion of secondary mediators also contribute to the initiation
of platelet activation. Key components of platelet signaling pathways are activated, including phospholipase C (PLC), protein kinase C (PKC),
and phosphatidylinositide-3-kinase (PI3K), supporting sustained platelet activation and thrombus formation through the initiation of cytoskele-
tal rearrangements, granule secretion, and activation of integrin aIIbb3. So as to limit thrombus growth and prevent the formation of occlusive
thrombi, platelets contain self-regulating negative feedback mechanisms that counteract positive signaling. These negative regulators include
immunoreceptor tyrosine-based inhibition motif (ITIM)-containing receptors, endothelial cell-selective adhesion molecule (ESAM), which nega-
tively regulates integrin aIIbb3 activity, phosphatases that counteract phosphorylation-dependent positive signaling, and receptor desensitization,
which reduces the platelets’ response to secondary mediator signaling. TxA2, thromboxane A2.
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tors of platelet activation such as Rap1b, which controls
integrin aIIbb3 affinity, and is phosphorylated at Ser179
by PKA and PKG, causing it to be relocated away from
the cell membrane, and downstream effectors of platelet
activation [6]. Cyclic nucleotides are also strong inhibitors
of the release of Ca2+ into the cytosol, which underpins
many events in platelet activation, including regulation of
the Ca2+-dependent Rap1 guanine nucleotide exchange
factor (GEF), CALDAG-GEFI [7]. Phosphorylation of
the inositol 1,4,5-trisphosphate (IP3) receptor by PKA
and PKG inhibits its function as a Ca2+ channel, and
prevents Ca2+ release into the cytosol from the dense
tubular system (DTS) [2]. Targets specific to PKA include
proteins involved in cell adhesion and spreading, such as
Ga13 and GPIbb. cGMP regulates cyclic nucleotide levels
by activating phosphodiesterase (PDE)2A and PDE5A,
which degrade cAMP and cGMP, respectively, but also
inhibits PDE3A activity, reducing constitutive cAMP
degradation [2].
Platelets from humans deficient in PKG have enhanced
Ca2+ responses to agonists, indicating a role for cGMP-
mediated inhibition of Ca2+ release pathways [8]. Mice
lacking PKG have a prothrombotic phenotype and
increased intravascular adhesion and aggregation follow-
ing ischemia [9]. Mice deficient in the IP receptor show
enhanced platelet activation, highlighting the importance
of Gs-coupled receptors that regulate cAMP in suppress-
ing platelet activation [10]. Additionally, deletion of
the IP receptor in atherosclerosis-prone apolipopro-
tein E-deficient mice significantly accelerates the develop-
ment of atherosclerosis, which may be attributable, in
part, to increased platelet reactivity [11].
CD39
The endothelium and red blood cells can release several
molecules, such as ADP and ATP, that are capable of
stimulating platelets, and removal of these molecules is
essential for the prevention of unwanted activation.
CD39, an ectonucleotidase found at the platelet mem-
brane and on endothelial cells, prevents platelet activation
by hydrolyzing secreted ADP and ATP to AMP and ade-
nosine [12]. Adenosine activates the Gs-coupled adenosine
receptor, causing inhibition of platelets through elevation
of cAMP [13].
Junctional adhesion molecule A (JAM-A)
JAM-A, a member of the immunoglobulin superfamily of
surface membrane proteins, has been identified in human
platelets, and is thought to prevent platelet aggregation
and thrombus formation in resting platelets through inac-
tivation of integrin aIIbb3. In resting platelets, JAM-A is
phosphorylated and associates with integrin aIIbb3 to
allow the recruitment of C-terminal src kinase (Csk). Csk
regulates autoinhibition of c-Src through phosphorylation
of the inhibitory Tyr529 site of c-Src, thus preventing
c-Src-dependent phosphorylation and activation of inte-
grin aIIbb3 [14,15]. Upon strong agonist stimulation,
JAM-A is dephosphorylated, and this removes the brake
on integrin aIIbb3 activation. As a consequence of this,
mice deficient in JAM-A show a hyper-reactive platelet
phenotype [15].
Key regulators of activation
Following damage to the vascular endothelium, endoge-
nous inhibitory signals are overcome, enabling platelets to
react instantly to limit blood loss at sites of vascular
injury. Platelets located close to the vessel wall within the
blood flow come into contact with exposed extracellular
matrix proteins such as collagen, and this, in combination
with vascular shear forces, enables them to adhere to the
site of injury and aggregate to form a thrombus [1]. Plate-
lets bind to the collagen-containing adhesive surface
through glycoprotein (GP)Ib–V–XI via von Willebrand
factor (VWF) in the presence of high shear forces. Activa-
tion of the platelet receptors for collagen, integrin a2b1
and GPVI enables stable adhesion and initiates platelet
signaling and activation [16]. The release of secondary
mediators such as ADP and thromboxane A2 (TxA2)
amplifies the platelet response and subsequent activation
of the coagulation pathway at the platelet surface. Expo-
sure of phosphatidylserine (PS) on the surface of highly
activated platelets enables assembly of the prothrombi-
nase complex and the generation of thrombin. Thrombin
is a potent platelet activator that can stimulate and
enhance platelet aggregation and thrombus formation
through the protease-activated receptors (PARs) [17].
Thrombin also stabilizes the growing thrombus by cleav-
ing fibrinogen to form a fibrin mesh.
These activating stimuli ultimately regulate a core set
of signaling mediators that support activation. Three cen-
tral mediator families of platelet activation are PLC,
PKC, and PI3K, which are well characterized and under-
lie two of the critical events in platelet activation, i.e.
secretion of secondary mediators and activation of
integrin aIIbb3. These are by no means the only critical
regulators of platelet function, but they represent key
nodes in the complex network of platelet signaling that
regulate many other important signaling elements (Fig. 2)
[18–21].
PLC activation
Activation of PLC is a critical event in platelet activation,
because it gives rise to two of the most important activa-
tory signaling molecules in platelets. PLC family members
catalyze the cleavage of phosphatidylinositol 4,5-bispho-
sphate (PIP2) to generate diacylglycerol (DAG), which
activates PKC, and IP3, which binds to IP3 receptors on
the DTS of platelets to activate Ca2+ flux into the
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cytosol. Patients with low platelet PLC activity fail to
respond normally to platelet agonists and even to Ca2+
ionophore, only achieving normal aggregation following
addition of the direct PKC activator DiC8 [22]. This is
because both Ca2+ release and PKC activation are criti-
cal for integrin aIIbb3 activation and secretion. How and
when the two main PLC isoforms in platelets, PLCc2 and
PLCb, are activated therefore determines platelet
activation.
PLCc2 is activated downstream of immunoreceptor tyr-
osine-based activation motif (ITAM)-bearing (consensus
sequence Yxx[L/I]x6–12Yxx[L/I]) adhesion receptors in
platelets, i.e. GPVI-FcRc/FccRIIA and C-type lectin
receptor 2 (CLEC-2) (which bears a half-ITAM motif
[hemITAM]) [23]. The pathway that activates PLCc2 is
complex, and involves assembly of a signaling protein
complex, the linker of activated T cells (LAT) signalo-
some, around the scaffolding protein LAT, which is phos-
phorylated and activated by Syk downstream of Src
family kinases [24]. Activation of PLCc2 requires binding
of Slp76 to LAT via Gads, which enables Btk [25,26] to
phosphorylate PLCc2 [27]. Clustering induced by collagen
and fibrinogen binding to integrins a2b1 and aIIbb3,
respectively, also stimulates PLCc2 signaling, although
for this LAT is not required [28]. Owing to its role in the
signaling cascade of receptors that mediate interactions
stimulated by matrix proteins, PLCc2 plays a significant
role in initial platelet adhesion and thrombus formation.
Genetic deletion of PLCc2 in mice results in severely
diminished thrombus formation following minor laser-
induced vessel injury, whereas its role was less significant
following major injury, when thrombin generation plays a
greater role [29].
PLCb is activated by Gq-coupled GPCRs such as P2Y1
(ADP receptor), TP (TxA2 receptor), and PAR1 and
PAR4 (activated by thrombin). PLCb is an important
mediator of signaling evoked by the secreted, soluble sec-
ondary mediators ADP and TxA2, and therefore mediates
positive feedback signaling and recruitment of platelets to
growing thrombi. The consequences of preventing PLCb
activation via gene deletion of Gq in mice is profound,
because it is the major route to Ca2+ release and PKC
activation in platelets that are not in direct contact with
matrix proteins [29].
PKC activation
PKC constitutes a family of several different isoforms
that play key regulatory roles in platelet intracellular sig-
naling. Several isotypes/isoforms of PKC have been iden-
tified in platelets, and are divided into three different
subtypes according to their structures and mechanisms of
regulation: the conventional (classic) PKCs, i.e. PKCa,
PKCbI/II, and PKCc, which require both DAG and
Ca2+ for full activation; the novel PKCs, i.e. PKCd,
PKCh, PKCg, and PKCe (only in mice), which require
DAG binding but are insensitive to Ca2+; and the atypi-
cal PKCs, i.e. PKCf and PKCι/k, which are insensitive to
both DAG and Ca2+. Expression of some isoforms in
platelets is controversial [19]. Phosphorylation at key reg-
ulatory sites by phosphoinositide-dependent kinase-1
(PDK-1) and autophosphorylation prime PKC for second
messenger binding and activation [19]. Studies that have
utilized broad-spectrum inhibitors and mice deficient in
the individual isoforms of PKC have identified an overall
positive role for the PKC family in the regulation of
granule secretion, TxA2 synthesis, integrin activation,
aggregation, and thrombus formation [19]. Negative regu-
latory roles have also been identified, including roles in
receptor desensitization and Ca2+ release, although some
of the isoform-specific roles remain controversial [19,30–
32]. Substrates and targets of the PKC isoforms include
components of the secretion machinery, such as SNAP23,
syntaxin 4, and Munc18c, and cytoskeleton-associated
proteins, including pleckstrin, MARCKS, and vasodila-
tor-stimulated phosphoprotein (VASP), among other pro-
teins that have been shown to be phosphorylated in a
PKC-dependent manner [19]. These differences in func-
tion for the PKC family are attributed to different and
distinct roles for the different isoforms in cell signaling
and regulation, which could be attributable to different
modes of regulation, different substrate specificities, and/
or the association with distinct binding proteins and dif-
ferent subcellular localizations [33].
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Fig. 2. Phospholipase C (PLC), protein kinase C (PKC) and phos-
phatidylinositide-3-kinase (PI3K) are key mediators of platelet acti-
vation. All main activating platelet agonist receptors identified to
date activate at least one of the following key activatory signaling
mediators: PLC, PKC, or PI3K. These signaling nodes underlie sev-
eral key processes required for platelet activation, including secretion
of secondary mediators and activation of integrin aIIbb3, facilitating
fibrinogen binding and platelet aggregation, and also cytoskeletal
rearrangements, which enable platelet shape change and spreading.
CLEC-2, C-type lectin receptor 2; GPVI, glycoprotein VI (collagen
receptor); GPIb–IX–V, glycoprotein Ib–IX–V (von Willebrand factor
receptor); PAR, protease-activated receptor; P2Y1/P2Y12, ADP
receptors; TP, thromboxane A2 receptor; aIIbb3, receptor for fibrino-
gen; a2A, adrenergic receptor.
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PI3K activation
Appreciation of the role of class I PI3K in platelets as a
promoter of sustained activation and stable thrombus for-
mation has developed as its different functions have
become understood. All class I PI3K isoforms phospho-
rylate PIP2 to generate phosphatidylinositol 3,4,5-trispho-
sphate (PIP3), enabling signaling to or recruitment of
proteins containing PH domains to the plasma mem-
brane. This is believed to localize signaling kinases within
close proximity of their downstream effectors. One such
protein is the Ser/Thr kinase protein kinase B (Akt),
which has numerous targets but is believed to exert some
of its effects via inhibition of glycogen synthase kinase 3
(GSK3). Inhibition of GSK3 appears to potentiate
responses to thrombin but not to GPVI agonists such as
collagen [34]. Following stimulation with thrombin,
PKCa mediates early phosphorylation of GSK3, whereas
phosphorylation by Akt occurs at later time points [35].
Mitogen-activated protein kinases such as extracellular
signal-regulated kinase (ERK) are also downstream effec-
tors of PI3K, with an apparently minor role downstream
of GPVI [36,37]. PI3K has an important role in the regu-
lation of Btk and its substrate PLCc2 by causing them to
colocalize at the plasma membrane [38].
Mice deficient in each type I PI3K expressed in plate-
lets have been generated and characterized [39]. PI3Kd is
expressed at low levels, and genetic deletion or knock-in
of a catalytically non-functional form had little measur-
able impact on platelet function. PI3Kc is predominantly
involved in signal transduction downstream of P2Y12, but
plays a semi-redundant role with PI3Kb downstream of
GPCRs. PI3Kb is the dominant form downstream of
GPVI, where it has a role in PLCc2 activation and Ca2+
elevation [40]. PI3Ka is believed to function cooperatively
with PI3Kb downstream of GPVI, where it also has a
role in PLCc2 activation [40,41], possibly through the reg-
ulation of Btk. PI3K-dependent activation of PDK-1 may
also contribute to the regulation of PKC activation.
Key events during platelet activation
Cytoskeletal rearrangement
Platelet activation is associated with major changes in the
actin cytoskeleton that initially support shape change and
later allow platelets to spread once they come into con-
tact with adhesive surfaces such as exposed collagen or
other platelets. Shape change occurs rapidly when plate-
lets are stimulated; it results in the formation of pseu-
dopodia that increase platelet surface area, and is
dependent on Ca2+ elevation mediated by Gq or activa-
tion of G13, which couples to the small GTPase Rho.
Rho mediates cytoskeletal reorganization through activa-
tion of myosin light chain kinase. Cytoskeletal reorgani-
zation enables relocalization of platelet granules and
organelles to the center of the platelet, the transient for-
mation of filopodia, and the sustained formation of
lamellipodia, which enables secretion and spreading over
the area of vessel damage [42]. For spreading to occur,
activation of either PLCb or PLCc, mobilization of intra-
cellular Ca2+, the generation of phosphoinositides and
activation of integrin aIIbb3 are required [43]. Rapid reor-
ganization of the actin cytoskeleton is characterized by a
combination of uncapping, severing and nucleation of the
actin filaments, and interaction with and activation of
myosin II [44]. Several regulators of these processes have
been identified, including the Rho GTPases Rac, Cdc42
and RhoA, VASP, and PKC [19,45–47].
Secretion of secondary mediators
Secretion or release of secondary mediators is critical for
the positive feedback that supports clot consolidation,
but can also serve as the primary activating signal for pla-
telets encountering an established and growing thrombus.
The most prominent secondary mediators are ADP and
TxA2. Like integrin aIIbb3 activation, the secretion path-
ways are dependent on several convergent signaling path-
ways activated by multiple receptors.
Granule secretion
Platelets contain different types of granule, including the
dense granules, which contain high concentrations of the
secondary mediators ADP and 5-hydroxytryptamine, and
the a-granules, which contain many coagulation and
adhesive proteins. The mechanisms governing the secre-
tion of both types of platelet granule appears to be lar-
gely shared, and involve assembly of a secretion complex
containing soluble NSF-associated attachment protein
receptor (SNARE) proteins such as the vesicle-associated
membrane proteins (VAMPs) [48], and SNARE regula-
tors such as Munc13-4 [49]. Ca2+ has a critical role in
granule secretion in all cell types, but the precise mecha-
nism of Ca2+-mediated granule secretion in platelets is
unclear. It is believed that the Ca2+-sensing protein
calmodulin mediates phosphorylation of myosin light
chain [50], leading to interaction with VAMP and the
exocytotic cell machinery, causing granule secretion [51].
Slp1 inhibits dense granule secretion until the inhibition is
relieved by binding of Rap1GAP2, although the role of
Ca2+ in the process is unclear [52].
The DAG mimetic and PKC activator phorbol 12-myr-
istate 13-acetate can induce granule secretion in the
absence of intracellular Ca2+ elevation [53]. Although it
has long been understood that PKCs have a net positive
regulatory role in granule secretion, the precise roles of
the different isoforms are difficult to dissect. Negative
roles for both PKCd and PKCh following stimulation by
GPVI agonists have, however, been described [19]. Many
key regulators of granule secretion, such as Munc18c,
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syntaxin-4, and SNAP23, are phosphorylated, and there-
fore potentially regulated, by PKCs [54–56].
As a consequence of the complex crosstalk between
pathways, the secreted secondary mediators have a role in
potentiating secretion, creating an unintuitive, cyclical
relationship. For example, following GPVI activation,
P2Y12 responds to secreted ADP by potentiating granule
secretion via activation of Rac1, leading to an increase in
ADP secretion and further activation of P2Y12 and
P2Y1 [57].
TxA2 synthesis
TxA2 is synthesized de novo upon platelet activation. Syn-
thesis is mediated by a cascade of enzymes, including
cyclooxygenase-1, the target of aspirin, but it is regulated
at the level of liberation of arachidonic acid from mem-
branes by phospholipase A2. This enzyme is activated by
elevated Ca2+, which induces translocation to the plasma
membrane and phosphorylation by the stress kinase P38
[58] and ERK1/2 [59]. As is the case in granule secretion,
P2Y12 has a regulatory role in TxA2 synthesis, whereby
stimulation of platelets with ADP causes PI3K-dependent
TxA2 generation, which potentiates Ca
2+ signaling [60].
Novel secretion pathways
A novel platelet secretion mechanism has recently been
reported whereby ATP is secreted from pannexin
hemichannels to activate P2X1, the only ligand-gated
Ca2+ channel in platelets, causing influx of Ca2+. This
enhances activation stimulated by low concentrations of
GPVI agonists [61].
Integrin activation
In many ways, integrin aIIbb3 activation represents the
central point of platelet signaling pathways, as the major-
ity of inhibitory and activatory signaling pathways con-
tribute towards its regulation in some way. The activation
of integrin aIIbb3 is the culmination of a chain of signal-
ing events that induce a conformational change enabling
high-affinity binding of fibrinogen and VWF. Without the
capacity to bind fibrinogen, platelets are unable to adhere
to each other and form aggregates. The binding partners
that are assembled around integrin aIIbb3 and support
activation and association with the actin cytoskeleton
include talin [62] and kindlin [63]. The small GTPase
Rap1 is an important regulator of integrin aIIbb3 activa-
tion [57, 64], and appears to be the integrating point of
many platelet-activating signals. Elevation of Ca2+ modu-
lates Rap1 activation via the highly expressed platelet
GEF CalDAG-GEFI [65], which binds Ca2+ via EF-
hand domains to become activated [66]. Activation of
PI3K is another central event in sustained platelet activa-
tion, and this too modulates Rap1 [67]. PI3K has recently
been shown to act by inhibiting the GTPase-activating
protein RASA3, which negatively regulates Rap1 activa-
tion [68]. This mechanism might explain why activators
of PI3K, such as the ADP receptor P2Y12, are unable to
elicit integrin aIIbb3 activation unless positive regulation
via Ca2+ elevation or PKC occurs simultaneously. A
study using genetic reconstitution of the integrin aIIbb3
activation pathway in cell lines, RIAM, indicated that the
Rap1b effector was a critical mediator of integrin activa-
tion in platelets, linking the GTPase to integrin aIIbb3
[69]. However, a recent study has demonstrated that the
adaptor molecule might not have a critical role in plate-
lets, as platelet-specific RIAM deficiency in mice was not
accompanied by a platelet functional defect [70].
Advanced microscopy techniques are now revealing the
spatial and temporal regulation of integrin activation,
and have demonstrated that knowledge of the signaling
cascades that support activation of key platelet receptors
such as integrin aIIbb3 is only part of the story. Coordina-
tion of the cytoskeleton with clustering of adhesive recep-
tors and mediators of activation underlies the ability of
platelets to form stable aggregates under shear stress [71].
Negative feedback and self-regulation
Following initiation of platelet activation and thrombus
formation, negative signaling mechanisms restrain activa-
tion to ensure that platelet aggregation does not progress
out of control, thus preventing excessive thrombus
formation.
The pathways that contribute to negative regulation
have been studied less extensively than those that mediate
platelet activation, and consequently have not been fully
characterized. Negative regulators, such as immunorecep-
tor tyrosine-based inhibition motif (ITIM)-containing
receptors, are thought to reduce the activation of critical
players such as PLC, PI3K, and integrin aIIbb3 [72].
Other endogenous inhibitory mechanisms include
endothelial cell-selective adhesion molecule (ESAM),
Wnt–b-catenin, and semaphorin 3A (Sema3A), which
negatively regulate integrin aIIbb3 activity, phosphatases
that limit phosphorylation-dependent mechanisms, recep-
tor desensitization, which limits the response to secondary
mediator signaling, and intracellular nuclear receptors
with different mechanisms of action [73,74].
ITIM signaling
ITIM-containing proteins are predominantly associated
with negative regulation of platelet signaling and activa-
tion. The ITIM consensus sequence (L/I/V/S-x-Y-x-x-L/
V) in the cytoplasmic tail has been identified in several
proteins that are expressed in platelets, including platelet
endothelial cell adhesion molecule-1 (PECAM-1) [75,76],
carcinoembryonic antigen cell adhesion molecule-1 (CEA-
CAM-1) [77], carcinoembryonic antigen cell adhesion
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molecule-2 (CEACAM-2) [78], G6b-B [79,80], and
LILRB2/paired immunoglobulin-like receptor B (PIRB)
[81], all of which negatively regulate platelet activation.
PIRB is activated by binding of its endogenous ligand,
ANGPTL2, which is secreted by platelets [81]. In con-
trast, PECAM-1 appears to be activated by receptor clus-
tering that is stimulated by homophilic interactions [82].
For other ITIM receptors, it is not clear which type of
interaction might trigger activation, but their function
can be inferred from the phenotypes of mice with geneti-
cally induced deficiencies for different ITIM-containing
receptors. Activation of ITIM receptors evokes src family
kinase-dependent phosphorylation of the ITIM tyrosine
residues, which enables the recruitment of negative regu-
lators of platelet activation, including phosphatases such
as SHP1/SHP2 [83] and SHIP1/SHIP2, to the receptor
[84]. Binding to the ITIM brings these proteins in close
proximity to their substrates. The resulting inactivation of
tyrosine kinases such as Syk, inactivation of the LAT sig-
nalosome and PLCc2 and inhibition of PIP3 leads to
inactivation of PI3K and Akt, and inhibition of down-
stream signaling pathways [85]. Recruitment to the ITIM
can also result in the relocalization of molecules away
from other signaling partners, preventing further trans-
mission of positive signals such as that observed with
PECAM-1, which associates with PI3K and sequesters it
away from LAT, preventing its activation and down-
stream signaling [85].
ITIM-containing proteins were generally considered to
constitute the off ‘switch’ that counteracts the positive
signaling initiated by ITAM-bearing receptors, such as
GPVI-FcRc/FccRIIA, and CLEC-2 (which contains a
hemITAM). However, studies on PECAM-1 [75,76,86],
G6b-B [79,80] and LILRB2/PIRB [81] have identified
inhibitory regulatory roles following stimulation by
GPCR agonists and in the regulation of integrin aIIbb3
function, suggesting that their role is not solely limited to
inhibition of ITAM signaling. In support of an inhibitory
role in the regulation and limitation of platelet activation,
studies of thrombus formation in PECAM-1 [87], CEA-
CAM-1 [77], CEACAM-2 [78] or LILRB2/PIRB [81]
receptor-deficient mice have shown that the mice have
hyper-reactive platelets, increased thrombus size and
increased stability of thrombi as compared with wild-type
controls.
Interestingly, despite the negative roles of PECAM-1
and CEACAM-1 in the regulation of platelet activity, stud-
ies using either PECAM-1/ or CEACAM-1/ mouse
platelets show impaired outside-in signaling, as spreading
and adhesion on fibrinogen, clot retraction and phosphory-
lation of focal adhesion kinase are reduced in comparison
with wild-type platelets [88,89]. This indicates positive roles
for both PECAM-1 and CEACAM-1 in the regulation of
integrin aIIbb3 signaling following fibrinogen binding.
Human studies have revealed that the expression levels
of PECAM-1 on the surface of human platelets correlates
negatively with platelet reactivity to CRP-XL and ADP.
The contribution of PECAM-1 expression levels as a
determinant of platelet reactivity is around half that of
GPVI levels, demonstrating the importance of both
activatory and inhibitory pathways in controlling
responsiveness. [76].
Other negative regulators
ESAM, which is usually contained in the a-granules, is
translocated to the cell surface following platelet activa-
tion [90], and is suggested to be involved in the negative
regulation of integrin aIIbb3 outside-in signaling, as
ESAM-deficient mouse platelets show increased aggrega-
tion in response to GPCR agonists, inhibition of clot
retraction, increased thrombus formation in vivo, and
reduced tail bleeding [91]. The mechanism by which
ESAM functions is currently unknown, although interac-
tion with the scaffold protein NHERF-1 highlights the
possible regulation of several proteins, including GPCRs,
G-proteins, PLCb, and components of the cytoskeleton.
The neurophillin-1–plexin A receptor complex, which
has been identified in platelets [92], is activated by
Sema3A, which is secreted from endothelial cells [93] and
negatively regulates platelet function through regulation
of integrin aIIbb3. Integrin activation, aggregation, adhe-
sion and spreading are all impaired following Sema3A
binding. The exact mechanisms by which Sema3A binding
inhibits platelet function have yet to be fully elucidated;
however, inhibition of the GTPase Rac1 could play a role
[92].
Wnt3a is a GP that has been found to be released
from TRAP-stimulated platelets, enabling platelets to
self-regulate and limit activation [94]. In platelets, Wnt3a
is thought to activate the canonical Wnt–b-catenin sig-
naling pathway, as several components of this pathway
have been identified in platelets [94]. Wnt binding leads
to the inhibition of platelet adhesion and shape change,
dense granule secretion, integrin aIIbb3 activation, and
aggregation, possibly through regulation of the activity
of small GTPases, including Rap1, Cdc42, Rac1, and
RhoA [95].
Intracellular nuclear receptors have recently been iden-
tified in platelets and found to have a role in platelet inhi-
bition. Usually associated with genomic regulation of
transcription, these receptors have also been shown to
have non-genomic regulatory roles. Several intracellular
nuclear receptors have been identified and characterized
in human platelets, including peroxisome proliferator-acti-
vating receptor (PPAR)a, PPARb/d, PPARc, retinoid X
receptor (RXR), liver X receptor (LXR), and glucocorti-
coid receptor [96–100]. Treatment of platelets with ligands
for these receptors results in inhibition of platelet aggre-
gation in response to several platelet agonists, supporting
previously published cardioprotective effects of these
treatments [96–102]. The different nuclear receptors can
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interact with each other to form heterodimers, although,
to date, little is known about the interactions between
these receptors in platelets. There is some overlap in the
mechanisms by which they inhibit platelet activation,
highlighting possible points of receptor interaction.
Ligands for PPARa and PPARb/d appear to elicit their
inhibitory effects through regulation of cellular cAMP
levels [103], whereas PPARc and LXR ligands alter asso-
ciation of the receptor with components of GPVI and
integrin signaling pathways such as Syk, LAT, and
PLCc2 [96,98].
Protein modification by phosphorylation of tyrosine or
serine and threonine residues is a key reversible mecha-
nism of signal transduction. Dephosphorylation by phos-
phatases enables bidirectional regulation of signal
transduction and platelet function. Phosphatases, includ-
ing SHP1/SHP2, SHIP1/SHIP2, protein phosphatase (PP)
2, phosphatase and tensin homolog (PTEN), and T-cell
ubiquitin ligand-2 (TULA2), are integral mediators of
several negative signaling mechanisms in platelets prevent-
ing key platelet processes such as mobilization of intracel-
lular Ca2+, granule secretion, and integrin activation.
SHP2 has well-established roles in the negative regulation
of platelet signaling downstream of both GPCRs and
GPVI, and is a key mediator of ITIM receptor signaling
downstream of PECAM-1 and CEACAM-1, negatively
regulating proximal signaling events, leading to reduced
PLC activation and therefore reduced mobilization of
Ca2+ [73]. TULA2 dephosphorylates and inactivates Syk,
preventing signaling that has been shown in mathematical
modeling studies to be critical in determining the rate of
GPVI-mediated platelet activation [104]. The inositol
phosphatases PTEN and SHIP1 play key roles in altering
the phosphoinositide cycle and antagonizing PI3K func-
tion [105]. The role of the serine/threonine kinase phos-
phatase PP2A in the negative regulation of integrin aIIbb3
function and signaling has been attributed to the dephos-
phorylation of PKCf, and protein-tyrosine phos-
phatase 1B, which subsequently reduces Src
phosphorylation and activation [106–108]. Although sev-
eral phosphatases are associated with negative regulation
of platelet function, it is important to note that many
positive regulatory functions for phosphatases, e.g.
CD148, have also been identified in platelets [73].
Receptor desensitization enables platelets to regulate
their responsiveness to platelet agonists. The process of
receptor desensitization includes inactivation via phospho-
rylation events, and internalization, which removes recep-
tors from the plasma membrane. As previously described,
ADP is a critical secondary mediator of platelet activa-
tion, but the receptors for ADP are rapidly desensitized
following exposure to ADP, resulting in a subsequently
reduced agonist response [30,74]. This diminished
response is attributed to desensitization of both the P2Y1
and P2Y12 receptors via agonist-mediated internalization
through two different protein kinase-mediated pathways,
with P2Y1 desensitization being mediated by both classic
and novel isoforms of PKC, and P2Y12 desensitization
being mediated by GPCR kinase and the novel PKC iso-
forms [30,74]. In contrast, the PARs have been shown,
following platelet activation by thrombin or the PAR1
peptide agonist SFLLRN, to be internalized or shed into
membrane microparticles, resulting in a decrease in the
number of receptors detected at the platelet surface. This
decrease is thought to underlie the inability of platelets to
recover their responsiveness to PAR agonists [109].
Novel approaches to platelet signaling and future
directions
The understanding of platelet signaling has increased
exponentially in recent decades, and it is now clear that
the signaling that underpins platelet function is best
described as a heavily interlinked network rather than as
linear pathways (Fig. 3). The vast amount of data
describing the components within this network presents
new challenges regarding the best way to interpret and
transform this information into improved diagnostic and
therapeutic strategies. Progressive approaches to platelet
function screening have been developed that utilize stan-
dardized assay plate technology, bringing the high-
throughput methodologies of the drug discovery industry
into the clinical setting [110]. The ability to easily test
many parameters simultaneously may allow positive and
negative pathways to be investigated simultaneously and
enable more of the platelet signaling network to be con-
sidered during the diagnosis of platelet disorders. System-
atic measurement and analysis of platelet function under
flow is also a promising avenue of development, and pro-
vides a sensitive diagnostic approach under more physio-
logic conditions and incorporates many more aspects of
the platelet signaling network into the diagnosis of plate-
let disorders [111]. The use of both of these strategies in
combination with genetic mutant models, patient studies
and inhibitor screening would give us a thorough insight
into the roles of particular molecules in the regulation of
platelet activity as a whole.
Systems approaches that utilize mathematical modeling
are increasingly being applied to help in our understand-
ing of platelet biology. These can take two distinct forms:
those using a top-down approach, whereby the properties
of relatively intact and complex systems are modeled; and
those using a reductionist approach, whereby relatively
few aspects of platelet signaling or function are modeled,
but in greater detail. For example, the top-down
approach has revealed important details of how platelet
thrombi are organized into a highly activated, dense
‘core’ of PS-exposing platelets surrounded by a loosely
packed and partially activated ‘shell’ [112–114]. Reduc-
tionist models, in contrast, often focus on Ca2+ signaling,
as it is easy to measure with high temporal resolution and
to quantify, and is a point of signal integration
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downstream of many platelet pathways. Ca2+ models
have proved to be useful in understanding how platelets
organize important functional events, such as PS expo-
sure, in subpopulations [115]. Modeling of the processes
that regulate cytosolic Ca2+ levels has provided insights
into the mechanism of store-operated Ca2+ entry and
release from the DTS via IP3 receptors [116]. Mathematical
modeling has aided the understanding of kinase regulation
downstream of GPVI and in particular the important role
that negative regulation by phosphatases, such as TULA2,
play in modulating signal transduction [104].
Future innovations will be required to integrate path-
ways into networks and to develop top-down and reduc-
tionist models until they are able to meet in the middle.
Such complex models will need to be validated by the use
of data from many different platelet donors, in order to
reflect the variability in platelet responsiveness that is pre-
sent within the human population. Such modeling of pla-
telet signaling networks will prove to be an important
future direction for the field, as it will be a requirement
for understanding how combinations of regulatory factors
contribute collectively to platelet function and predicting
how changes within specific parts of the network alter
platelet reactivity or levels of activation. This knowledge
will aid in the selection of proteins (individually or in
combination) representing promising new antithrombotic
targets, and will help in understanding the defects associ-
ated with an increased risk of thrombosis.
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Fig. 3. Complexity of platelet signaling networks. Platelet signaling models frequently describe signaling pathways activated by individual ago-
nists; however, platelet signaling in vivo is highly complex, and involves simultaneous activation by multiple agonists and negative regulators,
which form a complex signaling network. Several key signaling molecules, i.e. phospholipase C (PLC), protein kinase C (PKC), and phos-
phatidylinositide-3-kinase (PI3K), are common between the different pathways and form key nodes of platelet regulation. Blue boxes and lines
represent mediators of inhibitory signaling that act to suppress platelet function in the absence of platelet activators in the healthy endothelium.
Red boxes and lines represent mediators of activatory signaling following platelet activation by platelet agonists. Green boxes and lines repre-
sent mediators of negative feedback and inhibitory signaling that act to limit platelet activation following stimulation by platelet agonists.
CALDAG-GEFI, Ca2+-dependent Rap1 guanine nucleotide exchange factor; CEACAM-1/2, carcinoembryonic antigen cell adhesion molecule-
1/2; CLEC-2, C-type lectin receptor 2; ESAM, endothelial cell-selective adhesion molecule; GP, glycoprotein; IP, prostaglandin receptor; IP3R,
inositol trisphosphate receptor; ITIM, immunoreceptor tyrosine-based inhibition motif; JAM-A, junctional adhesion molecule A; LAT, linker
of activated T cells; PAR, protease-activated receptor; PECAM-1, platelet endothelial cell adhesion molecule-1; PIRB, paired immunoglobulin-
like receptor B; PKA, protein kinase A; PKG, protein kinase G; PLA2, phospholipase A2; sGC, soluble guanyl cyclase; TULA2, T-cell ubiqui-
tin ligand-2; TxA2, thromboxane A2; VASP, vasodilator-stimulated phosphoprotein; a2A, adrenergic receptor.
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